Prostate Patents (Class 514/19.5)
-
Patent number: 8586543Abstract: The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.Type: GrantFiled: August 17, 2009Date of Patent: November 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Ahmed A. Samatar, Brian Long, Priya Dayananth, Diane Levitan, Marsha Smith
-
Publication number: 20130302357Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Patent number: 8580743Abstract: A recombinant galectin 9 (rGal 9) is provided which exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response.Type: GrantFiled: August 22, 2012Date of Patent: November 12, 2013Assignee: Galpharma Co., Ltd.Inventors: Nozomu Nishi, Mitsuomi Hirashima, Akira Yamauchi, Aiko Ito
-
Publication number: 20130295106Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.Type: ApplicationFiled: March 13, 2013Publication date: November 7, 2013Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Publication number: 20130288984Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof.Type: ApplicationFiled: January 11, 2012Publication date: October 31, 2013Applicant: GLAXOSMITHKLINE LLCInventor: Rakesh Kumar
-
Publication number: 20130274203Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.Type: ApplicationFiled: September 14, 2011Publication date: October 17, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventor: Dhanalakshmi Chinnasamy
-
Patent number: 8557777Abstract: The present invention is directed to prostate specific antigen (PSA) and tumor endothelial marker 8 (TEM8) peptide compositions and methods for treating cancer with the compositions.Type: GrantFiled: March 6, 2012Date of Patent: October 15, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Supriya M. Perambakam, David J. Peace
-
Patent number: 8551951Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: GrantFiled: January 22, 2010Date of Patent: October 8, 2013Assignee: Aenorasis SA Pharmaceuticals and Medical DevicesInventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Publication number: 20130244949Abstract: The present invention relates a prophylactic or therapeutic composition for cancer, and more particularly, to a pro-phylactic or therapeutic composition for cancer comprising a peptide which is represented by an amino acid sequence of the following Formula (I), a method for preventing or treating cancer comprising the step of administering the peptide to a subject, and use of the peptide in the preparation of the prophylactic or therapeutic composition for cancer. (I) APKAMX1LLX2X3L-LX4LQKKGI wherein X1, X2, X3 and X4 are each independently R or K.Type: ApplicationFiled: December 24, 2010Publication date: September 19, 2013Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Sun Chang Kim, Su A Jang, Da Jung Kim, Bong Hyun Sung, Ki Jeong Lim, Ju Ri Shin, Young Woong Lee
-
Patent number: 8536132Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.Type: GrantFiled: February 10, 2011Date of Patent: September 17, 2013Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of CaliforniaInventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
-
Publication number: 20130225503Abstract: Embodiments of the present invention regard TEX14 peptides for cancer treatment. In particular, the TEX14 peptides comprise a GPPX3Y motif. Methods, compositions, and kits are encompassed.Type: ApplicationFiled: September 30, 2010Publication date: August 29, 2013Applicant: Baylor Licnensing GroupInventors: Martin M. Matzuk, Tokuko Iwamori, Michael P. Greenbaum, Lang Ma, Naoki Iwamori
-
Publication number: 20130225478Abstract: Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.Type: ApplicationFiled: July 19, 2011Publication date: August 29, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yechiel Shai, Avner Fink, Eliran-Moshe Reuven, Liraz Shmuel-Galia
-
Patent number: 8518887Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.Type: GrantFiled: June 25, 2010Date of Patent: August 27, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
-
Patent number: 8518890Abstract: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.Type: GrantFiled: September 28, 2007Date of Patent: August 27, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahito Hara, Masami Kusaka
-
Patent number: 8518891Abstract: Chemotherapeutic conjugates of a peptide substrate to a phosphoramide chemotherapeutic agent in which a peptide substrate is covalently linked to the chemotherapeutic agent by a linker with an aminoarylmethyl or aminoheteroaryl moiety, wherein the linking of the peptide to the chemotherapeutic agent inhibits the cytotoxic activity of the chemotherapeutic agent, the peptide is a substrate for proteolytic cleavage by a tumor-specific enzyme; and the linker is capable of undergoing 1,6-elimination in vivo upon cleavage of the peptide substrate. Methods for synthesizing and methods of using the conjugates are also disclosed.Type: GrantFiled: November 29, 2007Date of Patent: August 27, 2013Inventors: Longqin Hu, Xinghua Wu
-
Patent number: 8513199Abstract: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.Type: GrantFiled: May 8, 2012Date of Patent: August 20, 2013Assignee: Amgen Inc.Inventors: Kenneth Allan Brasel, James F Smothers, Douglas Pat Cerretti
-
Publication number: 20130196927Abstract: A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its cIAP degradation properties.Type: ApplicationFiled: January 28, 2013Publication date: August 1, 2013Inventors: Christopher BENETATOS, Srinivas CHUNDURU, Stephen CONDON, Mark McKINLAY, Yasuhiro MITSUUCHI
-
Publication number: 20130189256Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: ApplicationFiled: January 29, 2013Publication date: July 25, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Publication number: 20130190250Abstract: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.Type: ApplicationFiled: September 14, 2012Publication date: July 25, 2013Inventors: Preeti G. Lal, Jennifer L. Jackson, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Susan K. Sather, Purvi Shah
-
Publication number: 20130189291Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.Type: ApplicationFiled: January 17, 2013Publication date: July 25, 2013Applicant: Oncotherapy Science, Inc.Inventor: Oncotherapy Science, Inc.
-
Patent number: 8492345Abstract: Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.Type: GrantFiled: November 14, 2011Date of Patent: July 23, 2013Assignee: Northwestern UniversityInventors: Richard B. Silverman, Shouxin Liu, Wenxin Gu, Thomas E. Adrian, Gerald A. Soff
-
Publication number: 20130184223Abstract: Disclosed are compositions and methods related to new targets for cancer treatment the modulation of autophagy.Type: ApplicationFiled: May 20, 2011Publication date: July 18, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Hartmut Land, Conan Kinsey
-
Publication number: 20130184224Abstract: The present invention provides a method for inhibiting androgen receptor (AR)-containing tumor cell growth in a subject in need thereof, comprising administrating to said subject a pharmaceutically effective amount of a damaged-DNA binding protein 2 (DDB2) and a pharmaceutically acceptable carrier. The present invention also provides a method for inhibiting androgen receptor (AR)-containing tumor cell growth in a subject in need thereof, comprising administrating to said subject a pharmaceutically effective amount of an expression vector comprising a gene encoding a damaged-DNA binding protein 2 (DDB2) and a pharmaceutically acceptable carrier. In a preferred embodiment, the expression vector is a plasmid vector.Type: ApplicationFiled: January 8, 2013Publication date: July 18, 2013Applicant: NATIONAL TAIWAN UNIVERSITYInventor: National Taiwan University
-
Publication number: 20130184201Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicants: Arizona State UniversityInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Publication number: 20130164218Abstract: This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein.Type: ApplicationFiled: December 27, 2012Publication date: June 27, 2013Applicant: EMORY UNIVERSITYInventor: EMORY UNIVERSITY
-
Publication number: 20130165381Abstract: The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y? is a pharmaceutically acceptable anion.Type: ApplicationFiled: January 16, 2013Publication date: June 27, 2013Applicant: SILENCE THERAPEUTICS AGInventor: SILENCE THERAPEUTICS AG
-
Patent number: 8470295Abstract: A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent.Type: GrantFiled: May 9, 2008Date of Patent: June 25, 2013Assignee: Peak Biosciences, Inc.Inventors: Stephen L. Warren, James E. Matsuura, Michael J. Gerber
-
Patent number: 8470783Abstract: A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.Type: GrantFiled: August 20, 2002Date of Patent: June 25, 2013Assignee: Astellas Pharma Inc.Inventors: Yuka Sasakawa, Yoshinori Naoe
-
Patent number: 8461117Abstract: The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.Type: GrantFiled: December 28, 2007Date of Patent: June 11, 2013Assignee: Medarex, Inc.Inventors: Bilal Sufi, Vincent Guerlavais, Liang Chen, Sanjeev Gangwar, Qian Zhang, David B. Passmore
-
Patent number: 8461118Abstract: Lytic peptides, including fusion peptides of lytic peptides conjugated with luteinizing hormone-releasing hormone or modified versions thereof to target luteinizing hormone-releasing hormone receptors, are disclosed. The lytic peptides show anti-proliferative activity against human prostate cancer cell lines, but are nontoxic to normal primary human prostate epithelial cells or to bone marrow stromal cells in co-culture. The lytic peptides have specificity for and anti-proliferative activity against prostate cancer tumor cells, and low toxicity for normal prostate cells, making the peptides useful in therapies for prostate cancer.Type: GrantFiled: July 7, 2011Date of Patent: June 11, 2013Assignee: Tuskegee UniversityInventors: Clayton Yates, Jesse Jaynes, Timothy Turner
-
Publication number: 20130142797Abstract: The present invention relates to methods of treating virus-induced cancer with the polypeptides that are capable of killing cells. The polypeptide comprises a targeting agent covalently attached to a channel-forming moiety.Type: ApplicationFiled: December 7, 2012Publication date: June 6, 2013Applicant: PHEROMONICIN BIOTECH, LTD.Inventor: PHEROMONICIN BIOTECH, LTD.
-
Publication number: 20130143811Abstract: Provided herein is tumor suppression composition and methods of making and using the same.Type: ApplicationFiled: May 25, 2011Publication date: June 6, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang
-
Publication number: 20130142867Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.Type: ApplicationFiled: October 25, 2011Publication date: June 6, 2013Applicant: Academia SinicaInventors: John Yu, Alice L. Yu, H.C. Wu, I-Ju Chen, Sheng-Hung Wang
-
Publication number: 20130137628Abstract: An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer-lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.Type: ApplicationFiled: May 11, 2011Publication date: May 30, 2013Applicant: ESPERION THERAPEUTICS, INC.Inventors: Roger S. Newton, Rai Ajit K. Srivastava, Timothy R. Hurley, Clay Cramer, Sergey V. Filippov, Stephen L. Pinkosky
-
Patent number: 8450283Abstract: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.Type: GrantFiled: September 10, 2009Date of Patent: May 28, 2013Assignee: National Taiwan UniversityInventors: Pan-Chyr Yang, Tse-Ming Hong, Yuh-Ling Chen, Ang Yuan, Yi-Ying Wu
-
Publication number: 20130129759Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.Type: ApplicationFiled: June 27, 2012Publication date: May 23, 2013Applicant: Oncotherapy Science, Inc.Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
-
Publication number: 20130130992Abstract: This invention relates to purified compound of formula (1). The invention includes all isomeric forms and all tautomeric forms of the compound of formula (1) and pharmaceutically acceptable salts thereof. The present invention further relates to processes for the production of the compound of formula (1) by fermentation of the fungal strain of sterile mycelium (PM0509732/MTCC5544) and to pharmaceutical compositions containing the compound as active ingredient and its use in medicines for treatment of cancer.Type: ApplicationFiled: August 5, 2011Publication date: May 23, 2013Applicants: ONCOTEST GMBH, PIRAMAL ENTERPRISES LIMITEDInventors: Sunil Kumar Jaiwant Rao Deshmukh, Shilpa Amit Verekar, Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyil, Kalpana Sanjay Joshi, Heinz-Herbert Fiebig, Gerhard Kelter
-
Publication number: 20130130989Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.Type: ApplicationFiled: April 27, 2011Publication date: May 23, 2013Inventors: Christopher John Brown, Cheng San Brian Chia
-
Patent number: 8445444Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).Type: GrantFiled: October 26, 2011Date of Patent: May 21, 2013Assignee: Phigenix, Inc.Inventor: Carlton D. Donald
-
Patent number: 8440620Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.Type: GrantFiled: August 29, 2011Date of Patent: May 14, 2013Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Patent number: 8435513Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: July 8, 2009Date of Patent: May 7, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Publication number: 20130109629Abstract: The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity.Type: ApplicationFiled: June 24, 2011Publication date: May 2, 2013Applicant: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Gernot Zissel, Joachim Müller-Quernheim, Antje Prasse
-
Publication number: 20130101588Abstract: The invention provides polypeptide, nucleic acid and other compositions. Polypeptide, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder, or reducing levels of LDL or oxLDL.Type: ApplicationFiled: August 2, 2010Publication date: April 25, 2013Applicant: PATRYS LIMITEDInventor: Heinz Peter Vollmers
-
Publication number: 20130102543Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.Type: ApplicationFiled: December 11, 2012Publication date: April 25, 2013Applicants: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of IllionisInventors: The Board of Trustees of the University of Illinois, Spectrum Pharmaceuticals, Inc.
-
Publication number: 20130101600Abstract: The invention relates to the use of CXCL5 as a marker for assessing hormone escape in prostate cancer cells. The invention further provides diagnostic methods and kits for assessing hormone escape in prostate cancer cells, and CXCL5 antagonists for use in the treatment or prevention of prostate cancer and/or hormone escape in prostate cancer.Type: ApplicationFiled: April 19, 2011Publication date: April 25, 2013Inventors: Gwendal Lazennec, David Vindrieux, Brigitte Madly
-
Publication number: 20130079288Abstract: Drugs are screened for affects on inhibiting efflux pumps and blocking gap junction communication in tumors by culturing cells to thereby form self-assembled spheroids and incubating the spheroids. Uptake of a substrate of the efflux pump and distribution of a substrate for the efflux pump within the spheroids is imaged to thereby select drugs that inhibit the efflux pump or do not block gap junction communication. Selected drugs can then be employed to treat a tumor.Type: ApplicationFiled: September 20, 2012Publication date: March 28, 2013Applicant: BROWN UNIVERSITYInventor: Brown University
-
Patent number: 8404643Abstract: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc.Type: GrantFiled: October 24, 2008Date of Patent: March 26, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa
-
Publication number: 20130064882Abstract: This relates to the prevention of cancer initiation. More specifically, the invention provides compositions and methods useful for altering the genetic signature in breast tissue, said alteration being correlated with a reduced risk for the development of breast cancer.Type: ApplicationFiled: April 8, 2011Publication date: March 14, 2013Applicant: FOX CHASE CANCER CENTERInventors: Jose Russo, Irma H. Russo
-
Publication number: 20130045214Abstract: Methods of screening for modulators of TRIM24 (also known as TIF1-ALPHA) expression and/or biological activity are described. In particular, methods of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and activity are provided and their use in treatment of cancer, particularly in breast, colon, prostate, renal cancers and in acute lymphoblastic leukemia. Suitable modulators of TRIM24 expression include siRNA and shRNA and can be used in the treatment of cancer and for targeting cancer stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 21, 2013Inventor: Michelle Barton
-
Publication number: 20130040894Abstract: The present invention relates to human serine/threonine kinase ULK3 and its ability to regulate GLI transcription factors; mediators of SHH signaling. This disclosure demonstrates that ULK3 enhances endogenous and over-expressed GLI1 and GLI2 transcriptional activity in cultured cells, and ULK3 alters subcellular localization of GLI1. According to this disclosure ULK3 is an autophosphorylated kinase and phosphorylates GLI proteins in vitro. A peptide sequence in GLI1 C-terminus that is phosphorylated by ULK3 is provided in this disclosure. ULK3 catalytical activity is shown to be crucial for its function in SHH pathway. This disclosure shows that serine/threonine kinase ULK3 is involved in the SHH pathway as a positive regulator of GLI proteins. Furthermore, a therapeutic method in SHH dependent human disorders is disclosed by pharmacological inhibition of ULK3 kinase activity. Identification of ULK3 substrate sequence in GLI1 allows the design of peptide-based modulators of its kinase activity.Type: ApplicationFiled: October 6, 2010Publication date: February 14, 2013Applicant: TALLINN UNIVERSITY OF TECHNOLOGYInventors: Priit Kogerman, Alla Maloverjan, Marko Piirsoo, Piret Michelson, Torben Osterlund